Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KMDA |
---|---|---|
09:32 ET | 1470 | 5.97 |
09:36 ET | 100 | 5.98 |
09:52 ET | 200 | 5.97 |
09:54 ET | 700 | 5.99 |
09:59 ET | 1000 | 5.94 |
10:17 ET | 1822 | 5.88 |
10:50 ET | 200 | 5.93 |
10:55 ET | 100 | 5.99 |
11:00 ET | 997 | 5.935 |
11:02 ET | 100 | 5.99 |
11:11 ET | 100 | 6 |
11:15 ET | 100 | 6 |
11:22 ET | 100 | 6 |
11:26 ET | 420 | 5.952 |
11:31 ET | 100 | 5.99 |
11:40 ET | 245 | 6 |
11:44 ET | 117 | 6 |
11:47 ET | 117 | 6 |
11:54 ET | 117 | 6 |
12:00 ET | 117 | 6 |
12:05 ET | 117 | 6 |
12:12 ET | 117 | 6 |
12:20 ET | 117 | 6 |
12:23 ET | 200 | 5.94 |
12:25 ET | 100 | 6 |
12:32 ET | 117 | 6 |
12:38 ET | 100 | 6.03 |
12:45 ET | 100 | 6.05 |
12:52 ET | 100 | 6.05 |
12:57 ET | 100 | 6.05 |
01:06 ET | 100 | 6.04 |
01:12 ET | 100 | 6.04 |
01:17 ET | 100 | 6.05 |
01:19 ET | 100 | 6.05 |
01:26 ET | 100 | 6.04 |
01:32 ET | 315 | 6.05 |
01:37 ET | 117 | 6.05 |
01:51 ET | 100 | 6.09 |
01:57 ET | 100 | 6.09 |
02:04 ET | 499 | 6.1 |
02:09 ET | 100 | 6.1 |
02:15 ET | 100 | 6.09 |
02:22 ET | 200 | 6.09 |
02:27 ET | 100 | 6.09 |
02:33 ET | 103 | 6.09 |
02:36 ET | 123 | 6.09 |
02:40 ET | 117 | 6.09 |
02:45 ET | 100 | 6.09 |
02:51 ET | 100 | 6.08 |
02:54 ET | 309 | 6.07 |
03:02 ET | 234 | 6.065 |
03:12 ET | 234 | 6.06 |
03:14 ET | 1300 | 6.05 |
03:38 ET | 100 | 6.05 |
03:43 ET | 100 | 6.045 |
03:45 ET | 100 | 6.045 |
03:48 ET | 100 | 6.04 |
03:50 ET | 1317 | 6.02 |
03:52 ET | 400 | 6.02 |
03:54 ET | 117 | 6.03 |
03:56 ET | 1285 | 6 |
03:57 ET | 200 | 6 |
03:59 ET | 3216 | 5.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kamada Ltd | 341.4M | 23.2x | -22.48% |
Sutro Biopharma Inc | 350.5M | -2.4x | --- |
Heron Therapeutics Inc | 467.0M | -5.0x | --- |
Anika Therapeutics Inc | 419.8M | -5.3x | --- |
Karyopharm Therapeutics Inc | 119.7M | -0.8x | --- |
Seres Therapeutics Inc | 206.0M | -2.2x | --- |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $341.4M |
---|---|
Revenue (TTM) | $149.5M |
Shares Outstanding | 57.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $0.26 |
Book Value | $4.25 |
P/E Ratio | 23.2x |
Price/Sales (TTM) | 2.3 |
Price/Cash Flow (TTM) | 13.5x |
Operating Margin | 9.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.